1. Khanna, M., Kumar, P., Choudhary, K., Kumar, B., & Vijayan, V. K. (2008). Emerging influenza virus: A global threat. Journal of Biosciences, 33, 475–482.
2. Akkina, R., Banerjea, A., Bai, J., Anderson, J., Li, M. J., & Rossi, J. J. (2003). si-RNAs, ribozymes and RNA decoys in modeling stem cell based gene therapy for HIV/AIDS. Anticancer Research, 23, 1997–2005.
3. Santoro, S. W., & Joyce, G. F. (1997). General purpose RNA-cleaving DNA enzyme. Proceedings of the National Academy of Sciences of the United States of America, 94, 4262–4266.
4. Banerjea, A. C., Chakraborti, S., Unwalla, H., Goila, R., Shrabani, S., Dash, B. C., et al. (2004). Potential therapeutic applications of DNA-enzymes and siRNAs against viral and cellular genes. In L. M. Khachigian (Ed.), Synthetic nucleic acids as inhibitors of gene expression: Mechanisms, applications, and therapeutic implications (pp. 115–134). Florida: CRC Press.
5. Kumar, P., Sood, V., Vyas, R., Gupta, N., Banerjea, A. C., & Khanna, M. (2010). Potent inhibition of influenza virus replication with novel siRNA-chimeric-ribozyme constructs. Antiviral Research, 87(2), 204–212.